Oh Chad 4
4 · AEON Biopharma, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
AEON Biopharma (AEON) CMO Chad Oh Receives Stock Awards
What Happened
Chad Oh, AEON Biopharma's Chief Medical Officer, received two awards of restricted stock units (transaction code A). On Feb 17, 2026 he was granted 862,500 RSUs (recorded at $0.00). On Mar 4, 2026 1,316,872 RSUs were recorded as acquired at $0.00 after a modification converting previously cash-settled RSUs to stock-settled RSUs. Total RSUs reported = 2,179,372; the $0.00 price reflects that these are awards (not open‑market purchases).
Key Details
- Transaction dates and amounts:
- Feb 17, 2026 — 862,500 RSUs granted (price $0.00). (Footnote F1)
- Mar 4, 2026 — 1,316,872 RSUs acquired at $0.00 via modification from cash-settled to stock-settled (Footnote F2).
- Vesting: Feb 17 grant vests in substantially equal installments on each of the first four anniversaries of Feb 17, 2026. The modified May 21, 2025 RSUs (F2) continue to vest in equal annual installments on each of the first four anniversaries of the May 21, 2025 grant date, subject to continued service.
- Shares owned after transaction: not specified in this filing.
- Prior reporting: the cash-settled RSUs were originally reported on a Form 4 filed May 23, 2025.
- Filing timeliness: Form 4 was filed Mar 11, 2026 reporting the Feb 17 and Mar 4 transactions; this is outside the typical 2-business-day window for Form 4s and therefore appears late.
Context
Restricted stock units (RSUs) are compensation that convert into shares (or cash) only upon vesting; these awards do not represent an immediate market purchase or sale. The Mar 4 action converted outstanding cash-settled RSUs (originally granted May 21, 2025) into stock-settled RSUs, meaning future vesting will deliver shares rather than cash. Such grants are common executive compensation and should be viewed as potential future dilution rather than an immediate statement of buying/selling by the insider.
Insider Transaction Report
- Award
Class A Common Stock
[F1]2026-02-17+862,500→ 866,564 total - Award
Class A Common Stock
[F2]2026-03-04+1,316,872→ 2,183,436 total
Footnotes (2)
- [F1]Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
- [F2]Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.